Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 4/20 | 0.34 |
| ▸ | GABRD | O14764 | 4/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.34 |
| ▸ | GABRE | P78334 | 4/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5324357 | 0.77 | ESR1 (0.43) | KDM4EALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL3608419 | 0.77 | GAA (0.41) | KDM4EALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL5535377 | 0.77 | ABCB1 (0.36) | NOTUMCYP1A2 | |
| SCHEMBL5474340 | 0.75 | NR4A1 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL769225 | 0.74 | — | — | |
| SCHEMBL21295791 | 0.73 | MAPT (0.43) | KDM4EALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL5542643 | 0.72 | NOTUM (0.40) | NOTUM | |
| SCHEMBL314750 | 0.72 | EGFR (0.47) | KDM4EALDH1A1LMNARAB9ANPC1 | |
| SCHEMBL4417646 | 0.71 | — | — | |
| SCHEMBL5535370 | 0.68 | AHR (0.50) | KDM4EALDH1A1RAB9ANPC1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101775020-A | Poly-substituted chromone pyrrole compound and synthetic method and application thereof | UNIV SUN YAT SEN | 2010-07-14 | — | — | CN | claimed |
| US-20060052365-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | claimed |
| JP-2006505526-A | — | — | 2006-02-16 | — | — | JP | claimed |
| EP-1539178-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004017911-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101775020-B | Poly-substituted chromone pyrrole compound and synthetic method and application thereof | UNIV SUN YAT SEN | 2012-06-27 | — | — | CN | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| EP-0891976-A1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5462940-A | 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0599968-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0598061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993004061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052365-A1 | Protease inhibitors | CTSS, CTSE, CMA1 | KDM4E 2095/4885ALDH1A1 1528/4885LMNA 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.